Summary
Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2016’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)
- The report reviews pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics and enlists all their major and minor projects
- The report assesses Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
AbbVie Inc.
Actelion Ltd
Alkermes Plc
Amarna Therapeutics B.V.
Antisense Therapeutics Limited
Biocon Limited
Biogen, Inc.
Cognosci, Inc.
F. Hoffmann-La Roche Ltd.
Forward Pharma A/S
GeNeuro SA
GlaxoSmithKline Plc
Iltoo Pharma
InteKrin Therapeutics, Inc.
Mapi Pharma Ltd.
MedImmune, LLC
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neurotec Pharma SL
Novartis AG
Octapharma AG
Opexa Therapeutics, Inc.
RedHill Biopharma Ltd.
Teva Pharmaceutical Industries Ltd.
Xenetic Biosciences (UK) Limited
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Relapsing Remitting Multiple Sclerosis (RRMS) Overview 11
Therapeutics Development 12
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) – Overview 12
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) – Comparative Analysis 13
Relapsing Remitting Multiple Sclerosis (RRMS) – Therapeutics under Development by Companies 14
Relapsing Remitting Multiple Sclerosis (RRMS) – Therapeutics under Investigation by Universities/Institutes 16
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Relapsing Remitting Multiple Sclerosis (RRMS) – Products under Development by Companies 20
Relapsing Remitting Multiple Sclerosis (RRMS) – Products under Investigation by Universities/Institutes 23
Relapsing Remitting Multiple Sclerosis (RRMS) – Companies Involved in Therapeutics Development 24
AB Science SA 24
AbbVie Inc. 25
Actelion Ltd 26
Alkermes Plc 27
Amarna Therapeutics B.V. 28
Antisense Therapeutics Limited 29
Biocon Limited 30
Biogen, Inc. 31
Cognosci, Inc. 32
F. Hoffmann-La Roche Ltd. 33
Forward Pharma A/S 34
GeNeuro SA 35
GlaxoSmithKline Plc 36
Iltoo Pharma 37
InteKrin Therapeutics, Inc. 38
Mapi Pharma Ltd. 39
MedImmune, LLC 40
Merck KGaA 41
Mitsubishi Tanabe Pharma Corporation 42
Neurotec Pharma SL 43
Novartis AG 44
Octapharma AG 45
Opexa Therapeutics, Inc. 46
RedHill Biopharma Ltd. 47
Teva Pharmaceutical Industries Ltd. 48
Xenetic Biosciences (UK) Limited 49
Zydus Cadila Healthcare Limited 50
Relapsing Remitting Multiple Sclerosis (RRMS) – Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 57
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
(clarithromycin + clofazimine + rifabutin) - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
aldesleukin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ALKS-8700 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
amiselimod hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATL-1102 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AZ-17 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Cellular Immunotherapy for Relapsing Remitting Multiple Sclerosis - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
cladribine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
COG-133 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
daclizumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
diazoxide - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
dimethyl fumarate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
glatiramer acetate ER - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
GNbAC-1 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
GSK-239512 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Guanabenz - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
HR-411 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
hydralazine - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
IB-MS - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
imilecleucel-t - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
immune globulin (human) - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
inebilizumab - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
INT-131 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
interferon beta-1b - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
interferon beta-1b - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
itolizumab - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
laquinimod sodium - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
M-2736 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
masitinib - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
MyeloXen - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
ocrelizumab - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
ofatumumab - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
opicinumab - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Pegylated Interferon-Beta-1b - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
ponesimod - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
siponimod - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Xemys - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Relapsing Remitting Multiple Sclerosis (RRMS) – Recent Pipeline Updates 140
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 187
Relapsing Remitting Multiple Sclerosis (RRMS) – Discontinued Products 189
Relapsing Remitting Multiple Sclerosis (RRMS) – Product Development Milestones 190
Featured News & Press Releases 190
Apr 12, 2016: Teva to Present Data on laquinimod at 68th AAN Annual Meeting 190
Mar 31, 2016: RedHill Announces Interim Results from Phase IIa PoC Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis 190
Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 194
Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 196
Jun 25, 2015: Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial 197
Jun 09, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis 198
Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 198
Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis 200
Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 200
Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 202
Appendix 203
Methodology 203
Coverage 203
Secondary Research 203
Primary Research 203
Expert Panel Validation 203
Contact Us 203
Disclaimer 204
List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2016 12
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Development by Companies, H1 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by AB Science SA, H1 2016 24
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by AbbVie Inc., H1 2016 25
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Actelion Ltd, H1 2016 26
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Alkermes Plc, H1 2016 27
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Amarna Therapeutics B.V., H1 2016 28
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Antisense Therapeutics Limited, H1 2016 29
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Biocon Limited, H1 2016 30
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Biogen, Inc., H1 2016 31
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Cognosci, Inc., H1 2016 32
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 33
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Forward Pharma A/S, H1 2016 34
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by GeNeuro SA, H1 2016 35
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by GlaxoSmithKline Plc, H1 2016 36
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Iltoo Pharma, H1 2016 37
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by InteKrin Therapeutics, Inc., H1 2016 38
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Mapi Pharma Ltd., H1 2016 39
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by MedImmune, LLC, H1 2016 40
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Merck KGaA, H1 2016 41
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 42
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Neurotec Pharma SL, H1 2016 43
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Novartis AG, H1 2016 44
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Octapharma AG, H1 2016 45
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Opexa Therapeutics, Inc., H1 2016 46
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by RedHill Biopharma Ltd., H1 2016 47
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 48
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 49
Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline by Zydus Cadila Healthcare Limited, H1 2016 50
Assessment by Monotherapy Products, H1 2016 51
Assessment by Combination Products, H1 2016 52
Number of Products by Stage and Target, H1 2016 54
Number of Products by Stage and Mechanism of Action, H1 2016 58
Number of Products by Stage and Route of Administration, H1 2016 61
Number of Products by Stage and Molecule Type, H1 2016 63
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics – Recent Pipeline Updates, H1 2016 140
Relapsing Remitting Multiple Sclerosis (RRMS) – Dormant Projects, H1 2016 187
Relapsing Remitting Multiple Sclerosis (RRMS) – Dormant Projects (Contd..1), H1 2016 188
Relapsing Remitting Multiple Sclerosis (RRMS) – Discontinued Products, H1 2016 189
List of Figures
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2016 12
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 51
Number of Products by Top 10 Targets, H1 2016 53
Number of Products by Stage and Top 10 Targets, H1 2016 53
Number of Products by Top 10 Mechanism of Actions, H1 2016 57
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 57
Number of Products by Routes of Administration, H1 2016 60
Number of Products by Stage and Routes of Administration, H1 2016 60
Number of Products by Top 10 Molecule Types, H1 2016 62
Number of Products by Stage and Top 10 Molecule Types, H1 2016 62
